tbuckley/cabot-search huggingface dataset:
AB0709 Pulmonary arterial hypertension in systemic lupus erythematosus: a study of 80 tunisian patients
Authors: S. Sayhi, F. Ajili, T. Filali, I. Gharsallah, L. Metoui, N. Ben Abdelhafidh, J. Laabidi, F. Msadak, B. Louzir, H. Haouala, S. Othmani
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Pulmonary hypertension (PH) is a serious form of pulmonary complication that occurs in Systemic lupus erythematosus (SLE). It is less frequent in SLE compared to systemic sclerosis. The symptoms of PH in SLE are non-specific and so it is under-recognized.There are several potential causes of PH in SLE including thromboembolic disease, pulmonary vasculitis, hypoxia and fibrosis due to interstitial lung disease. The treatment is based on a combination corticosteroid and immunosuppressive. Anticoagulants are indicated in cases of anti phospholipid syndrome (APS). <h3>Objectives</h3> This study aim is to estimate the prevalence of PH in SLE detected by echocardiography. <h3>Methods</h3> This is a retrospective study of 80 patients with SLE fulfilling the criteria of the ACR (American College of Rheumatology), followed in the Department of Internal Medicine of the Military Hospital of Tunis from 2000 to 2010. Echocardiography with measurement of pulmonary artery pressure was performed in 72 patients. A mean pulmonary artery pressure above 30 mm Hg was used to define a PH. <h3>Results</h3> Ten patients (7%) had a pulmonary artery pressure more than 30 mmHg. Two of them had lung disease (the first one emphysematous lung and the other interstitial lung disease due to SLE). Three patients had mitral regurgitation. An anti phospholipid syndrome (APS) was noted in 4 cases (40%). Five other patients with SLE had a single PAH (50%). Anti-Sm antibodies were positives in 3 cases. <h3>Conclusions</h3> PH is a rare complication of SLE. Its detection is based on echocardiography. Its prognosis is poor and experts suggest that the underlying SLE should be aggressively treated with immunosuppressive therapy in addition to PH-specific treatment. <h3>References</h3> N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the european society of cardiology. Eur Heart J, 25 (2004), pp. 2243–2278 E. Badui, D. Garcia-Rubi, E. Robles, J. Jimenez, L. Juan, M. Deleze et al. Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients. Angiology, 36 (1985), pp. 431–441 L. Fauchier, P. Goupille, D. Babuty, C. Marchal, J.P. Valat, J.P. Fauchier et al. Precapillary pulmonary arterial hypertension disclosing systemic lupus erythematosus. Arch Mal Coeur Vaiss, 89 (1996), pp. 477–480 <h3>Disclosure of Interest</h3> None Declared
FRI0416 Cd4+Cd25high Foxp3+ T Regulatory Cells and Related Cytokines (IL-6, IL-10, TGF-β) in Neuropsychiatric Systemic Lupus Erythematosus
Authors: K. Tselios, A. Sarantopoulos, I. Gkougkourelas, A.-M. Georgiadou, M. Pantoura, A. Psarras, P. Boura
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Dysfunction of peripheral immune tolerance against self antigens is a critical factor in the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) and is mainly mediated by T regulatory cells (Tregs). <h3>Objectives</h3> Aim of the present study was the evaluation of Tregs and related cytokines (IL-6, IL-10, TGF-β) in regard to disease activity in NPSLE patients. <h3>Methods</h3> Twenty patients (17 females, 3 males, mean age 44.9±14.1 years, mean disease duration 87.2±63.4 months) were included. CD4+CD25<sup>high</sup>FOXP3+ Tregs were assessed by triple color flow cytometry in 88 peripheral blood samples (26 active, 62 inactive disease). IL-6, IL-10 and TGF-β were evaluated by ELISA in 36 serum samples (18 active, 18 inactive disease). Disease activity was determined using SLEDAI (SLE Disease Activity Index). Statistics were performed by Student9s t-test; <i>p</i>&lt;0.05 was considered significant. <h3>Results</h3> Tregs were significantly lower in active NPSLE (0.57±0.17% of CD4+ T cells vs 1.05±0.39%, absolute numbers 4.6±3.4 vs 9.3±6.6 cells/mm<sup>3</sup>, <i>p</i>&lt;0.001). Serum IL-6 was significantly higher in active disease (6.1±2.4pg/ml vs 2.8±3pg/ml, <i>p</i>=0.005). On the contrary, IL-10 levels were not differentiated (4.5±3.2pg/ml vs 2.75±3.77pg/ml, <i>p</i>=0.224), while TGF-β was marginally lower in active disease (20064±5495pg/ml vs 25770±9282pg/ml, <i>p</i>=0.103). <h3>Conclusions</h3> Peripheral Tregs are lower in active NPSLE, in parallel with higher IL-6 and lower TGF-β levels. Impairment of the IL-6/TGF-β axis probably plays an important role in disease pathogenesis. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3813
FDG PET/CT in Primary Pulmonary Lymphoepithelioma-like Carcinoma
Authors: Aisheng Dong, Jian Zhang, Yang Wang, Zhijun Zhai, Changjing Zuo
Journal: Clinical Nuclear Medicine (2013)

Primary pulmonary lymphoepithelioma-like carcinomas are extremely rare tumors with better prognosis than other types of non–small cell lung cancer. An 83-year-old man presented with cough and hemoptysis for 2 weeks. Chest CT images showed a cylinder-shaped lesion in the right upper lung. 18F-FDG PET/CT showed strong FDG uptake (SUVmax, 34.5) of the tumor with ipsilateral hilar lymph node metastases. Video-assisted thoracoscopic lobectomy was performed. Histopathologically, the tumor was composed of epithelial tumor cells with high proliferation index (80%) and abundant lymphoplasmacytic cells, consistent with lymphoepithelioma-like carcinoma.
Cosmetic Surgery: Principles and Practice
Authors: Paul W. Greeley
Journal: JAMA (1960)

A reviewer of any new surgical text always hopes that many new and promising procedures will be described therein. Unfortunately, these were not found in the present volume. Much of the contents consist of a compilation of previously published works by other authors. The title itself is somewhat misleading since only a small portion of the book deals with purely cosmetic surgery. However, much of it deals with tumor surgery and the reconstructive procedures for correction of traumatic lesions. I fear that if patients carrying surgical insurance benefits apply for allowances, the insurance carriers could use this text as a basis to refuse payments since even the repair of post-traumatic deformities could be considered cosmetic surgery. This book does not offer any great contribution to the specialty of general plastic surgery.
Fish Oil and Diabetes: The Net Effect
Authors: Alexander Sorisky, David C Robbins
Journal: Diabetes Care (1989)

Fish Oil and DiabetesThe Net Effect There is no doubt about it, fish oils are the new dietary craze.Health-food stores and pharmacy shelves are stocked with bottles bearing a label adorned with the smiling face of an atherosclerotic-free Eskimo who devours whale blubber with reckless abandon.Fish oil capsules are definitely in, and Nike training shoes and Sony Walkmans are out.The public has heartily embraced the notion that omega-3 is the effortless way to evade a coronary.We can only assume that a fair proportion of our diabetic patients are also caught up in this new nutritional wave.But should we encourage this behavior?Omega-3 fatty acids (co3FAs) are polyunsaturated hydrocarbons believed to be the active components of fish oils.*They modify lipoprotein and eicosanoid metabolism, lower whole-blood viscosity, increase fibrinolytic activity, and decrease arterial blood pressure.In addition, they may alter cell membrane properties and the functions of certain membrane-bound proteins (1).Epidemiologic studies report a significant association between fish oil consumption and decreased incidence of cardiovascular disease (2).Regular ingestion of large amounts significantly lowers plasma triglyceride (TG) concentrations, possibly via inhibition of very-low-den-
Hypertrophic gastric folds caused by metastatic prostate adenocarcinoma
Authors: E. Krones, R. Stauber, M. Vieth, C. Langner
Journal: Endoscopy (2012)

The stomach represents an unusual site for metastatic lesions, and secondary tumors mimicking diffusely infiltrating primary gastric cancer are exceptionally rare [1]. With respect to prostate cancer, metastases to the upper gastrointestinal tract have only infrequently been described, and published data are mainly confined to single case reports [2] [3] [4].
PREDICTION OF MAJOR BLEEDING IN REVASCULARIZED PATIENTS WITH ACUTE CORONARY SYNDROMES: DEVELOPMENT OF A NOVEL BIOMARKER-BASED CLINICAL PREDICTION MODEL
Authors: Daniel Lindholm, Johan Lindbäck, Stefan James, Richard Becker, Jan Cornel, Anders Himmelmann, Evangelos Giannitsis, Robert Harrington, Claes Held, Steen Husted, Hugo Katus, Kenneth Mahaffey, Philippe Gabriel Steg, Robert Storey, Agneta Siegbahn, Christoph Varenhorst, Lars Wallentin
Journal: Journal of the American College of Cardiology (2016)
UTILIDAD DE LA PUNCIÓN ASPIRACIÓN CON AGUJA FINA GUIADA POR ECOENDOSCOPIA (USE-PAAF) EN LOS TUMORES NEUROENDOCRINOS (TNE) DE PÁNCREAS
Authors: N Alonso, L Argüello, M Reolid, M Ponce, M Bustamante-Balén, V Pons
Journal: Endoscopy (2014)

Introducción: Utilidad de la punción aspiración con aguja fina guiada por ecoendoscopia (USE-PAAF) en los tumores neuroendocrinos (TNE) de pancreas.
Treatment Considerations for the Cardiometabolic Signs of Polycystic Ovary Syndrome
Authors: Errol L. Fields, Maria E. Trent
Journal: JAMA Pediatrics (2016)

Polycystic ovary syndrome is characterized by an excess in androgen levels, ovarian dysfunction, and polycystic ovarian morphology but is also associated with metabolic dysfunction and risk factors for cardiovascular disease. To our knowledge, there are few therapeutic recommendations for these cardiometabolic risk factors and little evidence of their long-term clinical relevance to cardiovascular health.To determine metabolic and/or cardiovascular outcomes in polycystic ovary syndrome treatment literature since the publication of the most recent Endocrine Society clinical practice guidelines in 2013.We searched PubMed using a string of variations of polycystic ovary syndrome, therapy/treatment, and adolescence, and we included English-language original research articles published while the 2013 clinical practice guidelines were disseminated (ie, articles published from January 1, 2011, to June 1, 2015). Articles that appeared relevant based on a review of titles and abstracts were read in full to determine relevancy. References from relevant articles were reviewed for additional studies.Four topic areas emerged: (1) lifestyle modification, (2) metformin vs placebo or estrogen-progestin oral contraceptives, (3) insulin-sensitizing agents, and (4) estrogen-progestin formulations. Most studies assessed the role of metformin as a monotherapy or dual therapy supplement and found significant benefit when including metformin in polycystic ovary syndrome treatment regimens. Studies showed improvements in cardiometabolic risk factors and, in several, androgen excess and cutaneous and menstrual symptoms. Studies were limited by sample size (range, 22-171), few adolescent participants, and short-term outcomes.Findings show potential for metformin and estrogen-progestin dual therapy but warrant longitudinal studies examining outcomes from adolescence through middle age to determine the effect on long-term cardiovascular health.
TCT-820 Transcatheter Aortic Valve Implantation (TAVI) In Patients Unsuitable For A Transfemoral Approach: A Comparison Between Trans-apical and Trans-Axillary Approaches
Authors: Jason Leung Kwai Chan, Raymond Cartier, Xavier Freixa, Ragui Ibrahim, Reda Ibrahim, Yoan Lamarche, Philippe Demers, Raoul Bonan, Anita Asgar
Journal: Journal of the American College of Cardiology (2012)
PWE-116 Association Of Faecal Calprotectin With Extent And Distribution Of Inflammation In Ibd
Authors: VI Astle, NR Lewis
Journal: Gut (2014)

<h3>Introduction</h3> Calprotectin is a protein released by neutrophils in response to the presence of inflammation in the bowel.<sup>1</sup> Faecal calprotectin (FC) has been shown to be useful in the diagnosis of inflammatory bowel disease (IBD) as it correlates with mucosal disease activity and can help to predict response to treatment or relapse.<sup>1–3</sup> Data from small, selected case series have observed FC correlates better with colonic rather than ileal Crohn’s disease (CD)<sup>4</sup> and median FC concentrations are higher in extensive or left-sided ulcerative colitis (UC) disease than in proctitis.<sup>5</sup> We report the association of FC concentration with extent and distribution of inflammation in consecutively performed tests at our centre. <h3>Methods</h3> All FC tests performed between 01/07/12 and 31/12/12 were systematically collected and associations with activity and distribution using endoscopic, histological and radiological data explored. Proximal disease was defined as inflammation affecting the terminal ileum and ascending colon; left-sided disease as inflammation limited to the colorectum distal to the splenic flexure and pan-colitis with inflammation extending proximal to the splenic flexure. <h3>Results</h3> 203 (n = 160 CD; n = 43 UC) patients with IBD had FC tests performed of whom 96 (47.3%) had endoscopic, histological or radiological evidence of active disease. The mean age of IBD patients was 44.7 (SD 17.0) years and 58% were female. The mean FC concentration was significantly higher in patients with active pan-colitis (1038.1 iu (SD 1104.1)) than in active left-sided disease (mean 820.2 iu (SD 1535.1)); p = 0.01. The mean FC concentration was significantly higher in active pan-colitis than in active proximal disease (mean difference -669.3 iu (95% CI-1046.3, -292.4)); p = &lt;0.001. There was no significant difference in the mean FC concentration between active proximal or left-sided disease (mean difference –451.5 (95% CI -965.9, 62.9) or between CD and UC (mean difference 148.5 (95% CI-369.1–666.1). <h3>Conclusion</h3> Mean FC concentrations are significantly higher in active pan-colitis than in active left-sided or proximal disease, perhaps reflective of the greater extent of inflammation. Further work is required to explore why FC concentrations are lower in proximal disease despite presence of active inflammation. <h3>References</h3> <i>World J Gastroenterol</i> 2012;18(46):6782–6789 <i>Gut</i> 2005:54:364–368 <i>Inflammatory Bowel Diseases</i> 2013;19(2):332–341 <i>Am J Gastroenterol</i> 2010:105:162–169 <i>Scandinavian Journal of Gastroenterology</i> 2011:46:1081–1091 <h3>Disclosure of Interest</h3> None Declared.
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
Authors: Uri A. Liberman, Stuart R. Weiss, Johann Bröll, Helmut W. Minne, Hui Quan, Norman H. Bell, Jose Rodriguez-Portales, Robert W. Downs, Jan Dequeker, Murray Favus, Ego Seeman, Robert R. Recker, Thomas Capizzi, Arthur C. Santora, Antonio Lombardi, Raksha V. Shah, Laurence J. Hirsch, David B. Karpf
Journal: New England Journal of Medicine (1995)

We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo or alendronate (5 or 10 mg daily for three years, or 20 mg for two years followed by 5 mg for one year); all the women received 500 mg of calcium daily. Bone mineral density was measured by dual-energy x-ray absorptiometry. The occurrence of new vertebral fractures and the progression of vertebral deformities were determined by an analysis of digitized radiographs, and loss of height was determined by sequential height measurements.
P1-14-04: Prolonged (≥1 Year) Exposure to First-Line Bevacizumab Combined with Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer Treated in a Routine Oncology Practice Study.
Authors: S Kuemmel, A Schneeweiss, FG Foerster, M Geberth, H Tesch, P Klare, C Schumacher, W Hollburg, U Soeling, M Schmidt
Journal: Cancer Research (2011)

Abstract Background: First-line bevacizumab (BEV) combined with weekly paclitaxel (PAC) significantly improves progression-free survival (PFS) and response rate (RR) vs PAC alone in HER2−negative metastatic breast cancer (mBC), as shown in E2100. The benefit of BEV combined with other chemotherapy (CT) agents was demonstrated in AVADO and RIBBON-1. BEV was continued for ≥1 year in 21% of patients in the global ATHENA safety study and in 42% of patients in the JO19901 single-arm Japanese study of BEV-PAC. We analyzed data from the subgroup of patients treated for ≥1 year in a German routine oncology practice study to provide insight into the safety and efficacy of prolonged first-line BEV-PAC. Methods: Patients who had received no prior CT for their mBC received BEV-PAC per the European label. Efficacy and safety were documented for up to 1 year (or until progression, death, or BEV discontinuation if earlier) with additional long-term follow-up. Data from patients treated with BEV for ≥1 year were extracted for this analysis. Results: By Jan 2011, data were available for 818 patients, of whom 157 (19%) had already received BEV for ≥1 year. Baseline characteristics of this subset relative to the overall population are summarized in the table. In 79% of those treated for ≥1 year, BEV was continued as a single agent after discontinuation of CT. The overall RR in patients treated for ≥1 year was 81% (complete response in 20%). Median PFS was 17.9 months (events in 44% of patients) vs 9.4 months in the overall population (events in 68%). Overall survival data are immature, as 81% of those treated for ≥1 year are still alive. The most common grade 3/4 adverse events in patients treated with BEV for ≥1 year were hypertension (11% of patients), pain (10%), and leukopenia (7%). There were no cases of gastrointestinal perforation, arterial thromboembolic event, or reversible posterior leukoencephalopathy syndrome in those treated for≥1 year. Analysis of adverse events according to time of onset is ongoing. Conclusions: A notable proportion of patients appear to derive benefit from prolonged exposure to first-line BEV-containing therapy. In the present analysis, baseline characteristics appeared more favorable in the subset of patients treated for ≥1 year than in the overall population. Efficacy data clearly have a bias towards improved outcome in those able to continue BEV for ≥1 year, as these patients had sustained disease control for ≥1 year. However, the efficacy of prolonged BEV-containing therapy is of interest and suggests that some patients achieve sustained disease control with continued first-line BEV-PAC with limited side effects. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-14-04.
INDICADORES DE CALIDAD EN COLONOSCOPIAS. OPORTUNIDAD DE MEJORA
Authors: MA Martínez Menéndez, MR Sánchez Sánchez, I Mañana Canteli, C Fernández Díaz, E Alexandre Hurlé, A Andicoechea Agorria, E Barbón Remis
Journal: Endoscopy (2011)

Introducción: Existe un número creciente de pacientes que se someten a una exploración endoscópica del colon y recto bien por presentar clínica o para despistaje de cáncer colorrectal. Las sociedades científicas han propuesto el uso de indicadores de calidad siendo la detección de adenomas y la intubación cecal los más comúnmente utilizados.
Abstract 1717: SATB1 expression increases resistance of bladder cancer cells to cisplatin
Authors: Shilpa Choudhary, Olga Voznesensky, Carol Pilbeam, John A. Taylor
Journal: Cancer Research (2011)

Abstract Background: SATB1 (special AT-rich sequence binding protein-1) is a nuclear protein involved in chromatin organization and gene regulation. Increased expression of SATB1 in breast and hepatocellular cancer cells has been shown to promote metastasis and multidrug resistance. We explored the effects of SATB1 expression in the high grade human bladder cancer cell line, HTB-5. Methods: HTB-5 cells were transfected with an shRNA construct for SATB1 or a non-silencing (NS) control. Nuclear protein and mRNA expression were measured by Western analysis and real-time PCR, respectively. Cells were counted on days 2-6 of culture, and DNA replication was measured by thymidine incorporation (TdR) on day 3. Cell cycle distribution and cell viability were analyzed by propidium iodide-Annexin V FITC flow cytometry in 3 independent experiments. Cells were treated with cisplatin (6 μM) for 3 days. Results: SATB1 mRNA and protein expression levels were 28-fold and 5-fold higher, respectively, in HTB-5 cells compared to UROtsa cells, a benign transformed human urothelial cell line. Expression of SATB1 was reduced 80% or more in shRNA transfected HTB-5 cells. Cell counts and TdR were decreased 20-23% (p&amp;lt;0.01) in SATB1 knockdown cells compared to NS controls. SATB1 knockdown was associated with a significant increase of 15% in G1/G0 and decrease of 18% in S-phase. There was no significant difference in cell viability between SATB1 knockdown cells and NS controls. However, cisplatin treatment resulted in a decrease in live cells from 61.9 ± 4.6% to 39.5 ± 5% (p&amp;lt;0.01) and an increase in apoptotic cells from 33.1 ± 4.4% to 56.1 ± 4.0% (p&amp;lt;0.01) in SATB1 knockdown cells compared to NS controls. Conclusions: SATB1 expression was higher in a malignant compared to benign urothelial cell line and was associated with increased proliferation and increased resistance to chemotherapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1717. doi:10.1158/1538-7445.AM2011-1717
Abstract 273: Protein kinase C-iota self regulates its expression by regulating the activity of the transcription factor Elk-1
Authors: Prajit Pillai P. Pillai, Mildred Acevedo-Duncan
Journal: Cancer Research (2011)

Abstract Protein kinase C-iota (PKC-ι), a member of the atypical PKC family of Ser/Thr kinases has been recognized as an oncogene. PKC-ι manifests its effect by targeting various aspects of cancer cells such as growth, invasion and survival. Bcr-Abl has been shown to regulate the activation of the transcription factor ELK-1 which in turn regulates the expression of PKC-ι. Alternatively, we hypothesize that PKC-ι self regulates its expression by directly regulating the activity of ELK-1. Our preliminary data from immunoprecipitation studies show that PKC-ι directly associates with Elk-1 in neuroblastoma and glioma cells. PKC-ι directly phosphorylated cytoplasmic Elk-1 at Ser 383 in these cells. It has been reported that phosphorylation of cytoplasmic Elk-1 at Ser 383 results in conformational change that promotes the nuclear translocation of Elk-1, increased DNA binding and upregulation of its transcriptional activity. Furthermore, our data from cell cycle analysis showed that the nuclear translocation of Elk-1 coincided with the phosphorylation of cytoplasmic Elk-1 by PKC-ι. Robust phosphorylation of cytoplasmic Elk-1 was observed in the G1/S cell cycle phases, however, as the cells entered the M-phase, no phosphorylation of ELK-1 was observed. Similarly, the cytoplasmic to nuclear ratio of Elk-1 decreased as the cells entered the M-phase suggesting the role of PKC-ι in the promoting the nuclear translocation of Elk-1. Thus, our data supports our hypothesis that PKC-ι self regulates its expression by regulating the transcriptional activity of Elk-1. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 273. doi:10.1158/1538-7445.AM2011-273
825 DEVELOPMENT AND MOLECULAR CHARACTERIZATION OF A ROBUST GENOTYPE 4 HEPATITIS C VIRUS SUBGENOMIC REPLICON
Authors: B. Peng, M. Yu, S. Xu, B. Han, Y.-J. Lee, K. Chan, Y. Tian, N. Pagratis, H. Mo, J. McHutchison, W. Delaney, G. Cheng
Journal: Journal of Hepatology (2012)